”Gilles is in the air” by ESSTS
Why a podcast?
To discuss the latest findings on Tourette syndrome, share stories, and create connections.
Every month, (we are only warming up!), we will talk about tics, associated comorbidities and lived experiences; our episodes are aimed at researchers, clinicians, patients and their families.
We shall interview authors whose papers have caught our attention, discuss hot topics that may seem controversial, share different ways of educating the community on TS and hopefully, we will all learn something about Tourette that we had yet to discover.
So please, tune in, turn up the volume, and keep on listening… 🎧
And if you find the episode interesting, hit subscribe and please share!
All content for Gilles is in the air is the property of ESSTS and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
”Gilles is in the air” by ESSTS
Why a podcast?
To discuss the latest findings on Tourette syndrome, share stories, and create connections.
Every month, (we are only warming up!), we will talk about tics, associated comorbidities and lived experiences; our episodes are aimed at researchers, clinicians, patients and their families.
We shall interview authors whose papers have caught our attention, discuss hot topics that may seem controversial, share different ways of educating the community on TS and hopefully, we will all learn something about Tourette that we had yet to discover.
So please, tune in, turn up the volume, and keep on listening… 🎧
And if you find the episode interesting, hit subscribe and please share!
Results from phase III study of Ecopipam for Tourette Syndrome
Gilles is in the air
21 minutes
1 week ago
Results from phase III study of Ecopipam for Tourette Syndrome
Key findings, limitations and clinical perspectives on the important phase III study of Ecopipam for TS; taking a closer look with Dr Don Gilbert.
Dr Gilbert is Professor of Neurology at Cincinnati Children’s Hospital Medical Center, where he established the Movement Disorders and Tourette Clinics in 1998 and conducts translational research and clinical trials.
Key references
Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 Receptor Antagonist, Ecopipam, for treatment of tics in Tourette Syndrome. Clinical Neuropharmacology, 2014. 37:26-30.
Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, Coffman KA, McCracken JT, Juncos J, Grant JE, Chipkin RE. Ecopipam, a D1 receptor antagonist, for treatment of Tourette Syndrome in Children: A randomized, placebo-controlled crossover study. Movement Disorders 2018. 33: 1272-1280.
Chipkin RE, Gilbert DL, Mahableshwarkar A. Ecopipam: A D1 receptor antagonist for the treatment of Tourette syndrome. International Review of Movement Disorders. Elsevier, Inc. 2022. doi
Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR. Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics 2023. doi: 10.1542/2020-000123. PMID: 36628546
Gilbert DL, Kim DJB, Miller MM, Atkinson SD, Karkanias GB, Munschauer FE, Wanaski SP, Cuniff TM. Safety and Effect of 12-month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome. Movement Disorders Clinical Practice. 2025. doi
Gilles is in the air
”Gilles is in the air” by ESSTS
Why a podcast?
To discuss the latest findings on Tourette syndrome, share stories, and create connections.
Every month, (we are only warming up!), we will talk about tics, associated comorbidities and lived experiences; our episodes are aimed at researchers, clinicians, patients and their families.
We shall interview authors whose papers have caught our attention, discuss hot topics that may seem controversial, share different ways of educating the community on TS and hopefully, we will all learn something about Tourette that we had yet to discover.
So please, tune in, turn up the volume, and keep on listening… 🎧
And if you find the episode interesting, hit subscribe and please share!
